The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose - 05/03/25
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Objectives |
We conducted a randomised controlled trial (RCT) to compare immunogenicity, reactogenicity and safety one month after a fourth COVID-19 mRNA or protein vaccine dose.
Methods |
This RCT recruited healthy adults in Melbourne, Australia, who had previously received three COVID-19 vaccine doses at least six months prior and had no SARS-CoV-2 infection in the last three months. The participants were randomised (1:1) to receive the bivalent mRNA vaccine (mRNA-1273.214/mRNA-1273.222, hereafter Moderna) or protein vaccine (NVX-CoV-2373, hereafter Novavax) as a fourth dose. A self-selected control group who elected not to receive an additional dose were also included. The co-primary endpoints compared immunogenicity at 28 days post-vaccination measured as binding antibodies (IgG against Ancestral and Omicron subvariants; BA.1, BA.4/5 and JN.1) between the two vaccine groups, and reactogenicity within one-week post-vaccination. ClinicalTrials.gov Identifier: NCT05543356.
Results |
Between Feb 28 and Oct 4, 2023, 496 participants were enrolled into the study. Participants were randomised into either the bivalent mRNA Moderna (n=177) or protein Novavax (n=176) vaccine groups, with n=143 allocated to the control group. The geometric mean ratio (GMR) of anti-Spike binding IgG antibody levels were higher for the Moderna vaccine compared to the Novavax vaccine at 28 days post-vaccination for all variants tested, including Ancestral (GMR: 2.11, 95% CI: 1.88 – 2.37), BA.1 (GMR: 2.32, 95% CI 2.04 – 2.63), BA.4/5 (GMR: 2.32, 95% CI: 2.04 – 2.65), and JN.1 (GMR: 2.40, 95% CI: 2.14 – 2.70). The frequency of any local and systemic reactions (grades 1–4) was higher for the Moderna vaccine (159/177; 89.8%) compared to the Novavax vaccine (130/176; 73.9%). Serious reactions (grade 3–4) between the groups were similar (11/177; 6.2%, versus 9/176; 5.1%, respectively).
Conclusion |
At day 28 post-vaccination, higher immunogenicity was observed following Moderna vaccination compared to Novavax vaccination when given as a fourth dose in healthy adults for Ancestral and Omicron subvariants, including JN.1. However, local and systemic reactogenicity was higher in the Moderna vaccine group compared with the Novavax vaccine group. These results may have important implications for ongoing booster strategies.
Le texte complet de cet article est disponible en PDF.Highlights |
• | There is limited immunogenicity data of a fourth dose protein COVID-19 vaccine. |
• | Our RCT compared a fourth dose of mRNA and protein COVID-19 vaccines. |
• | Both vaccine groups had an immunogenic response to Ancestral and Omicron variants. |
• | Although serological GMR substantially favoured the mRNA vaccine group. |
• | Cellular immunity by IFNγ was similar between mRNA and protein vaccine groups. |
Keywords : COVID-19, SARS-CoV-2, Vaccination, Booster, Antibody, Immunity, Fourth dose
Plan
Vol 90 - N° 3
Article 106447- mars 2025 Retour au numéro
Article précédent
- Increasing child vaccination coverage can reduce influenza cases across age groups: An agent-based modeling study
- Katherine V. Williams, Mary G. Krauland, Mary Patricia Nowalk, Lee H. Harrison, John V. Williams, Mark S. Roberts, Richard K. Zimmerman
- Universal opt-out syphilis screening in a UK emergency department
- David Chadwick, Hannah Williams, Catriona Lane, Jane Knowles, Jim Woods, Sarah Bircham, Leanne Warters, Sandra Gittins, Buddhika Perera, Priyantha Batagalla, Kirsty Foster
Bienvenue sur EM-consulte, la référence des professionnels de santé.